Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
Update: 2025-01-10
Description
London-headquartered biotech startup Verdiva has emerged from stealth with a whopping $410mn for a new range of drugs aimed at tackling the obesity epidemic. It’s one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market. Verdiva looks to challenge the dominance of Novo Nordisk and Eli Lilly, the makers of the two most popular weight loss drugs, Ozempic and Wegovy. The company promises to offer less invasive pills, instead of injectables. Its most advanced product is an oral-based GLP-1, a drug that curbs hunger. Verdiva was founded in July 2024 by executives of Aiolos…
This story continues at The Next Web
Comments
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
